Brief: Harbour Biomed Enters Into Global Strategic Collaboration With Astrazeneca
21/03/2025 11:26
March 21 (Reuters) - Hbm Holdings Ltd 2142.HK: HARBOUR BIOMED ENTERS INTO GLOBAL STRATEGIC COLLABORATION WITH ASTRAZENECA TO DISCOVER AND DEVELOP NEXT-GENERATION THERAPEUTIC ANTIBODIES HBM HOLDINGS LTD - $105 MILLION EQUITY INVESTMENT BY ASTRAZENECA IN HARBOUR BIOMED HBM HOLDINGS LTD - HARBOUR BIOMED TO RECEIVE $175 MILLION UPFRONT AND UP TO $4.4 BILLION IN MILESTONES HBM HOLDINGS LTD - ASTRAZENECA TO ACQUIRE 9.15% NEWLY ISSUED SHARES OF HARBOUR BIOMED Source text: ID:nPn7kTr3da Further company coverage: 2142.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on HBM Holdings
See all newsBrief: HBM Holdings Says NMPA Approves Batoclimab Injection For Generalized Myasthenia Gravis
HBM climbs on development of AI biology foundation model
Brief: HBM Holdings' Unit Develops World's First Language Model For Fully Human Heavy-Chain-Only Antibodies
Brief: Hbm Holdings Says Solstice Oncology Launches Series A Financing Round
HK-listed HBM climbs on initiating next phase of asthma drug study